Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today highlighted data presented at the American Association ...

LAVAL, QC, April 21, 2026 /CNW/ - In recognition of AML World Awareness Day, Servier Canada is highlighting the progress made in precision medicine for Acute Myeloid Leukemia (AML). With TIBSOVO(R) ...

Decades after early trials seemed to close the book on vitamin C as a cancer treatment, a member of a group of determined researchers is receiving the therapy himself.

Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year survival below 30% ...

LMU researchers show that the chemotherapeutic drug azacitidine damages RNA and reveal a possible approach to improve therapies. Chemotherapeutics are designed to damage cancer cells in a targeted ...

NEW YORK – Sellas Life Sciences has enrolled the first patient in a Phase II trial of its CDK9 inhibitor tambiciclib in first-line acute myeloid leukemia (AML), the company announced this week. The ...

New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations. For decades, the “7+3” strategy—comprising 7 days of continuous ...

Chemotherapy-induced thrombocytopenia (CIT) is a common complication of chemotherapy that is associated with bleeding, reduced relative dose intensity, and potentially worse outcomes. No widely ...

G6PD deficiency links to higher remission and longer survival in AML patients on venetoclax plus azacitidine, suggesting a simple biomarker to guide treatment. An observational study recently ...

WASHINGTON, Jan. 14, 2026 /PRNewswire/ -- Blood Cancer United®, formerly The Leukemia & Lymphoma Society, announced today that the first patient has received treatment in a new sub-study of its Beat ...

Princess Kate is sharing a rare insight into her battle with cancer. The British royal, 43, opened up about her own experience with chemotherapy during a stop at Charing Cross Hospital in West London ...